# China SXT Pharmaceuticals

China SXT Pharmaceuticals is an Asset Manager based in Taizhou, China.

## Overview

- **Organization type:** Asset Manager
- **Headquarters:** Taizhou, China
- **Region:** Asia
- **Address:** Taizhou, Jiangsu, China
- **Assets under management:** Undisclosed

## Regulatory record

- **Reports private funds:** No

## About

China SXT Pharmaceuticals operates as a specialty pharmaceutical company originating from Taizhou, Jiangsu, a city known for China's traditional medicine industrial base. Feng Zhou led the firm's transition into an internationally listed entity, securing a Nasdaq listing under the ticker SXTC. The company focuses on researching, developing, and commercializing traditional Chinese medicine (TCM) pieces through advanced-drug delivery systems rather than simply commoditized raw herbs. Its anchor product, shengtaitong capsules, represents a patented granular formulation used for ischemic stroke rehabilitation, targeting the intersection of modern pharmacology and classical Chinese medicinal theory. The firm's deployment model centers exclusively on direct internal research and manufacturing, with no known allocations to external venture funds or private equity pools. Its asset-class mix is limited to pharmaceuticals, specifically within neurological and anti-inflammatory therapeutic areas. Beyond shengtaitong, the company holds patents for a portfolio including anti-depressive and immunomodulatory TCM formulations. Commercialization is targeted domestically through hospital and pharmacy distribution channels, with no confirmed international installations beyond its U.S. listing vehicle. The firm's geographic footprint remains concentrated in China, specifically Jiangsu province. Team size and precise deployment figures remain undisclosed. The firm maintains no named adjacent vehicles, philanthropic foundations, or known co-investor clubs. In September 2023, SXT Pharmaceuticals underwent a 1-for-25 reverse share split to regain Nasdaq minimum bid price compliance, signaling typical micro-cap balance-sheet management rather than growth-capital expansion. China SXT Pharmaceuticals differs structurally from a typical family-office investment platform: it is a publicly traded operating company where the manufacturing and science drive value rather than fund-of-funds or co-investment activities. Governance and succession are tied to Nasdaq board and audit committee requirements rather than family-office generational structures, making it an operational pharma manufacturer listed abroad, not a pooled investment vehicle.

## Sectors

- Healthcare Services

## People

- Feng Zhou — Chief Executive Officer

## Questions

### Who runs investment and operational decisions at China SXT Pharmaceuticals?

Feng Zhou serves as Chief Executive Officer and leads both strategic direction and operations. Public records do not indicate a separate CIO or investment committee common to family-office structures. Major corporate decisions are subject to Nasdaq-listed board governance and audit committee oversight.

### How does China SXT Pharmaceuticals source its proprietary pipeline?

The company sources through internal research and development of patented advanced-drug delivery systems. Its pipeline is generated in-house rather than acquired through venture investing. The lead asset, shengtaitong capsules, was developed from internal TCM formulation research.

### Which therapeutic areas does China SXT Pharmaceuticals target?

The firm targets neurological conditions with its lead product shengtaitong for ischemic stroke. Patent disclosures also indicate work on anti-depressive and immunomodulatory TCM formulations, concentrating entirely within specialty pharmaceutical applications of traditional Chinese medicine.

### Where does China SXT Pharmaceuticals' underlying asset value come from?

Value originates from its patent portfolio covering advanced-drug delivery systems for TCM pieces and from its manufacturing facility in Jiangsu, China. Public-market capitalization and periodic capital raises through its Nasdaq listing provide operating liquidity rather than a single-family wealth origin.

## Related profiles

- [VSee Health](https://altss.com/profile/vsee-health-inc)
- [Socket Mobile](https://altss.com/profile/socket-mobile-inc)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/china-sxt-pharmaceuticals-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology